---
schema_version: "secwatch.filing_event.v1"
accession: "0001553350-25-000111"
form_type: "8-K"
ticker: "PKTX"
cik: "0001128189"
company_name: "ProtoKinetix, Inc."
filed_at: "2025-11-21T23:59:59+00:00"
generated_at: "2026-05-16T17:32:30.489412+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "low"
source: SEC EDGAR
---

# ProtoKinetix CEO updates on founder Clarence Smith's passing and AAGP molecule strategy

## Summary
- CEO Guzzetta acknowledges sudden passing of longtime leader Clarence Smith and commitment to his vision.
- Company continues development of first-in-class synthetic glycopeptide AAGP (PKX-001) for cell protection and inflammation control.
- Global patent portfolio covers US, Europe, UK, Asia; outreach to pharma firms for Type 1 Diabetes, cell therapy, dry-eye, and topical applications.
- No financial or operational metrics provided; update is a stockholder letter with no specific milestones.

## SEC filing metadata
- accession: 0001553350-25-000111
- form_type: 8-K
- ticker: PKTX
- cik: 0001128189
- company_name: ProtoKinetix, Inc.
- filed_at: 2025-11-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1128189/000155335025000111/0001553350-25-000111-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1128189/000155335025000111/pktx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001553350-25-000111
- JSON: https://secwatch.observer/filing/0001553350-25-000111.json
- Plain text: https://secwatch.observer/filing/0001553350-25-000111.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.